•						OIPE 40
IDS Form PTO/S	B/08: Substitute for for	449A/PTO			Complete if Known	SEP 1 5 2005
				Application Number	0/523,014	\mathcal{Q}
INF	ORMATION D	ISCLOSU	IRF	Filing Date	February 1, 2005	13 .67
	TEMENT BY			First Named Inventor	Yannoni et al.	FRABBAN
514	ALCINENI DI	APPLICA	ria i	Art Unit	Not Yet Assigned 1	656
	(Use as many sheets	as necessary)		Examiner Name	Not Yet Assigned	Monshipowi
Sheet	1	of	3	Attorney Docket Number	08702.0097-00000	

Examiner Cite	Document Number	Issue or	Name of Patentee or	Pages, Columns, Lines, Where	
Initials	No.'	Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
16. TC.		US-4,522,811	06-11-1985	Eppstein et al.	
\neg		US-4,554,101	11-19-1985	Норр	
		US-4,609,546	09-02-1986	Hiratani	
-1		US-4,640,835	02-03-1987	Shimizu et al.	
		US-4,766,106	08-23-1988	Katre et al.	
_		US-4,791,192	12-13-1988	Nakagawa et al.	
$\neg f \dashv$		US-5,116,944	05-26-1992	Sivam et al.	
		US-5,414,135	05-09-1995	Snow et al.	
ren.		US-5,864,020	01-26-1999	Bennett et al.	

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

	FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
R.H.		.WO 87/05330	09-11-1987	Bergh et al.		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite Incl Initials No.1 (Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
18.K.		"Mammalian Matchmaker Two-Hybrid Assay Kit User Manual", Clontech, PR17119 (2001).	
re.19.		ALTSCHUL et al., "Basic Local Alignment Search Tool," J. Mol. Biol., 215(3):403-10 (1990).	
14.14.		APLIN AND WRISTON, "Preparation, Properties, and Applications of Carbohydrate Conjugates of Proteins and Lipids," CRC Crit. Rev. Biochem., 22:259-306 (1991).	
re.M.		BHADRA et al., "Pegnology: a review of PEG-ylated systems," Pharmazie, 57:5-29 (2002).	
H. P.		BURKE, "Protein-Protein Interactions, Pathways and Screens, 21-24 (March 2003).	-
١٤.١٩.		EDGE et al., "Deglycosylation of Glycoproteins by Trifluoromethanesulfonic Acid," Anal. Biochem., 118(1):131-37 (1981).	
ىر.ىر.		FALB et al., "Chemical Genomics: Bridging the Gap Between the Proteome and Therapeutics," Current Opinion In Drug Discovery & Development 5(4):532-39 (2002).	
R.M.		FIELDS AND SONG, "A Novel Genetic System to Detect Protein-Protein Interactions," Nature, 340:245-246 (1989).	
R.R.		FIELDS et al., "The Two-Hybrid System: An Assay for Protein-Protein Interactions," Trends in Genetics, 10:286-292 (1994).	
٠٤.٢٠.		FRALEY et al., "New Generation Liposomes: The Engineering of an Efficient Vehicle for Intracellular Delivery of Nucleic Acids," Trends Biochem. Sci., 6:77-80 (1981).	
re.M.		GUIDEZ et al., "Recruitment of the Nuclear Receptor Corepressor N-CoR by the TEL Molety of the Childhood Leukemia-Associated TEL-AML1 Oncoprotein," Blood, 96 (7):2557-2561 (2000).	
re.r<.		GUNSTER, et al., "Identification and Characterization of Interaction between the Vertebrate Polycomb- Group Protein BMI1 and Human Homologs of Polyhomeotic, Molecular and Cellular Biology, 17:2326-2335 (1997).	
r.n.		HAKIMUDDIN et al., "A Chemical Method of the Deglycosylation of Proteins," Arch. Biochem. Biophys., 259:52 (1987).	

IDS Form PTO/SB/08: Substitute for to 149A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

3

Sheet 2 of

Application Number 0/523,014 SEP 1 5 2005 W
Filling Date February 1, 2005
First Named Inventor Yannoni et al.
Art Unit Not Yet Assigned
Examiner Name Not Yet Assigned
Attorney Docket Number 08702.0097-00000

	NON PATENT LITERATURE DOCUMENTS				
10.1e.	HAN ET AL., "Emerging Targets for Anti-Inflammatory Therapy, Nature Cell Biology," 1:E39-40 (1999).				
n.19.	HARRIS et al., "Pegylation: A Novel Process for Modifying Pharmacokinetics," Clin. Pharmacokinet., 40:539-551 (2001).				
n.n.	HEIDENREICH, et al.," MAPKAP Kinase 2 Phosphorylates Serum Response Factor in Vitro and in Vivo," J. Biological Chemistry, 274(20):14434-14443 (1999).				
n. re.	HUANG et al. "LSP1 is the Major Substrate for Mitogen-activated Protein Kinase-activated Protein Kinase 2 in Human Neutrophils", Journal of Biological Chemistry, 272(1):17-19 (1997).				
R. R.	HUOT et al., "Oxidative Stress-Induced Actin Reorganization Mediated by the p38 Mitogen-Activated Protein Kinase/Heat Shock Protein 27 Pathway in Vascular Endothelial Cells," Cir. Res., 80(3):383-92 (1997).				
بو. ۶۰.	JANKNECHT, "Cell Type-specific Inhibition of the ETS Transcription Factor ER81 by Mitogen-activated Protein Kinase-activated Protein Kinase 2," J. Blological Chemistry, 276(45):41856-14861 (2001).				
٦٤.	KOTLYAROV et al., "Distinct Cellular Functions of MK2, Molecular and Cellular Biology," 22 (13):4827-4835 (2002).				
re.19.	KOTLYAROV et al., "MAPKAP Kinase 2 is Essential for LPS-induced TNF-α Biosynthesis," Nature Cell Biol., 1:94-97 (1999).				
رو. ۱۲.	KRÄMER, et al., "A Novel Isoform of the Smooth Muscle Cell Differentiation Marker Smoothelin", J Mol. Med., 77:294-98 (1999).				
re. re.	KYTE et al., "A Simple Method for Displaying the Hydropathic Character of a Protein," J. Mol. Biol., 157:105-132 (1982).				
۲۹.16.	LEHNER et al., "Mitogen-Activated Protein Kinase-Activated Protein Kinase 2-Dificient Mice Show Increased Susceptibility to Listeria Monocytogenes Infection", 168(9):4668-4673 (2002).				
re.re.	LIPMAN et al., "Rapid and Sensitive Protein Similarity Searches;" Science, 227(4693):1435-41 (1985).				
re.14.	LUBAN, et al., "The Yeast Two-Hybrid System for Studying Protein-Protein Interactions," Curr. Opinion Biotechnology, 6:59-64 (1995).				
re.re.	LUZI et al., "Evolution of Shc Functions from Nematode to Human," Curr. Opin. Genetics and Development, 10:668-674 (2000).	•			
re.re.	MAHTANI et al., "Mitogen-Activated Protein Kinase p38 Controls the Expression and Postranslational Modification of Tristetraprolin, a Regulator of Tumor Necrosis Factor Alpha mRNA Stability," Molecular and Cellular Biology, 21:6461-6469 (2001).				
بع.١٠	MANNINO et al., "Lipsome Mediated Gene Transfer," Biotechniques, 6(7):682-90 (1988).				
re. re.	MIGLIACCIO et al., "The p66 ^{shc} Adaptor Protein Controls Oxidative Stress Response and Life Span in Mammals," Nature, 402:309-313 (1999).				
۲۹.44.	NEININGER et al., "FRET-based Detection of Different Conformations of MK2," EMBO Reports, 2:703-708 (2001).				
18.14.	NEUFELD et al., "Serine/Threonine Kinases 3pK and MAPK-activated Protein Kinase 2 Interact with the Basic Helix-Loop-Helix Transcription Factor E47 and Repress Its Transcriptional Activity," J. Biological Chemistry, 275 (27):20239-20242 (2000).				
re.re.	PEARSON, et al., "Improved Tools for Biological Sequence Comparison," Proc. Natl. Acad. Sci. USA, 85:2444-2448 (1988).				
٦٩. ٢٢.	RANE, et al., "p38 Kinase-dependent MAPKAPK-2 Activation Functions as 3-Phosphoinositide-dependent Kinase-2 Akt In Human Neutrophils," J. Biological Chemistry, 276(5):3517-3523 (2001).				
12.19.	ROUSE et al., "A Novel Kinase Cascade Triggered by Stress and Heat Shock that Stimulates MAPKAP Kinase-2 and Phosphorylation of the Small Heat Shock Proteins", Cell, 78:1027-10237 (1994)				
16. Ls.	SHE et al., "ERKs and p38 Kinase Phosphorylate p53 Protein at Serine 15 in Response to UV Radiation, J. Biological Chemistry, 275,(27):20444-20449 (2000).				
بو. ۳۰	SHE et al., "Role of MAP Kinases in UVB-Induced Phosphorylation of p53 at Serine 20," Oncogene 21(10):1580-9 (2002).				
<i>دو.۴۹۰</i>	SMITH et al., "Overlapping Genes and Information Theory," J. Theor. Biol., 91(2):379-80 (1981).				
te.te.	SOJAR et al., "A Chemical Method for the Deglycosylation of Proteins," Arch. of Biochem. and Biophysics, 259 (1):52-57 (1987).				
18. Fe.	STOKOE et al. "The Substrate Specificity and Structure of Mitogen-Activated Protein (MAP) Kinase-Activated Protein Kinase-2," Biochem. J. 296:843-849 (1993).				
R.K.	THOTAKURA et al., "Enzymatic Deglycosylatin of Glycoproteins," Meth. Enzymol., 138:350-59 (1987).				
16.4.	TRINEI et al., "A p-53-p66Shc Signalling Pathway Controls Intracellular Redox Status, Levels of Oxidation-Damaged DNA and Oxidative Stress-Inducted Apoptosis," Oncogene 21(24):3872-78 (2002).				

SEP 1 5 200 plete if Known IDS Form PTO/SB/08: Substitute for fq 0/523,014 Application Number Filing Date February 1, 2005 INFORMATION DISCLOSURE Yannoni et al. First Named Inventor STATEMENT BY APPLICANT Not Yet Assigned Art Unit Examiner Name Not Yet Assigned 08702.0097-00000 Attomey Docket Number Sheet

	NON PATENT LITERA	TURE DOCUMENTS	
re. 4.	VAN DER LOOP, et al., "Smoothelin, a Novel Cytos Biology, 134 (2):401-411 (1996).		
re.re.	VIDAL et al., "Survey and Summary, Yeast Forward Research 27(4):919-929 (1999).	and Reverse 'n'-hybrid Systems,"	Nucleic Acids
re.re.	International Search Report, 08-22-2005		
Examiner Signature	rl. rlonshi	Date Considered	7/31/07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ine	Form	PTO/SB/08:	Substitute	for form	1449A/PT	ď
เบอ	rom	PIU/SB/US:	Substitute	IOI IOIIII	1440/07	

Sheet

INFORMAT STATEMEN

(Use as ma

			Application Number	10/523,014
ION I	DISCLOS	URE	Filing Date	February 1, 2005
IT BY APPLICANT			First Named Inventor	Yannoni
11 61	APPLIC	MIN İ	Art Unit	1860 1656
ny sheet	s as necessary)		Examiner Name	Monshipouri, Maryam
	of		Attorney Docket Number	08702 0097-00000

Complete if Known

		U.S. PATENTS	AND PUBLISHE	D U.S. PATENT APPLICAT	IONS .	
Examiner	Cite	Document Number	Issue or	Name of Patentee or	Pages, Columns, Lines, Where	
Initials	No.1	Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
		US-	·			
		US-				
		US	1			
		US-				
		US-				
		US-		· · · · · · · · · · · · · · · · · · ·		
		US-				
		US-				
		US-		· • • · · · · · · · · · · · · · · · · ·		
		US-				
		US-		•		

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

	FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶

		NONPATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
4. re.		Upton, J., "California's non-profit community blood bank system," California Medical Association, 73: 1950-52 (1950).	
18.19.		Plath, K., et al., "Characterization of the proline rich region of MAPKAP kinase 2: influence on catalytic properties and binding to the C-ABL SH3 domain in vitro," Biochemical and Biophysical Research Communications, 203: 1188-94 (1994).	
18. pe.		Supplementary partial European Search Report, mailed May 23, 2007	
R. M.		Honma, S., et al. "The influence of inflammatory cytokines on estrogen production and cell proliferation in human breast cancer cells," Endocrine Journal, 49: 371-77 (2002).	
re. r.		Yannoni, Y., et al., "P66sth A interacts with MAPKAP kinase 2 and regulates its activity," FEBS Letters, 564: 205-11 (2004).	

Examiner Signature	P. Floreki	Date Considered 7/27/07